Introduction
Partial or total occlusion of a coronary artery, primarily by a thrombus formed at the site of an atherosclerotic plaque is an atherothrombotic event of considerable clinical importance. To prevent a secondary event in these patients, anti-platelet therapy is given as one of the key treatment options [1, 2] . Nevertheless, mortality of patients with acute coronary syndrome (ACS) remains relatively high [3, 4] . Better characterization of ACS patients at high risk for having a secondary event may help in the development of individually "tailored" therapies and thus improve survival.
The vascular endothelium is an important regulator of coronary blood flow [5] and it has been suggested that endothelial perturbation predicts adverse clinical outcomes in patients with angina pectoris [6] and acute myocardial infarction [7, 8] . Von Willebrand Factor (VWF) is a prominent marker of endothelial perturbation and plays an important role in the interplay between platelets and the sub-endothelium. Upon rupture of an atherosclerotic plaque, VWF is essential for platelet adhesion, the first step in thrombus formation and occlusion of a coronary artery [9] . Physical evidence for involvement of VWF in platelet thrombus growth is provided by the detection of VWF in coronary thrombi [10] . Under shear conditions, VWF supports the adhesion and rolling of platelets on the endothelium [11, 12] . Subsequently, platelets are activated and platelet granule contents are released into the circulation. The most abundant proteins released from platelet α-granules have inflammatory and mitogenic properties [13] . As such, they enable the migration of monocytes to the site of the inflammation, activate endothelial cells and create a pro-coagulant environment [14] . Recently, it has been suggested that in ACS patients, markers of endothelial perturbation, with VWF in particular, are useful for detecting progression and prognosis, while markers of coagulation and platelet activation are valuable in aiding the treatment [12, 15] . Beneficial effects of therapies improving endothelial function in preventing secondary events have also been described [16] [17] [18] [19] .
In this prospective cohort study, we have investigated the relation of platelet and endothelial cell activation markers to mortality in ACS patients. In total, 339 patients with confirmed ACS were analyzed for six Thrombosis Research 131 (2013) 198-203 markers. Three of the markers: RANTES, NAP-2 and TSP-1 were markers of platelet activation. The other three: VWF, VWF:pp and OPG were markers of endothelial activation.
Materials and methods

Patients
The study included 339 consecutive patients with ACS who underwent PCI. Diagnosis of ACS was established on the basis of characteristics of anginal status, electrocardiographical and enzymatic criteria. All patients had angiographically-proven coronary artery disease. Angiographic diagnosis of coronary artery disease was based on the presence of coronary stenoses with ≥75% lumen obstruction in at least 1 of the 3 major coronary arteries. Antithrombotic treatment consisted of clopidogrel (600 mg as a loading dose followed by 75 mg/day continued from at least 4 weeks up to 1 year) and aspirin (200 mg/day continued indefinitely). Congestive heart failure was graded according to the New York Heart Association (NYHA) classification. Blood samples were obtained at the time of admission and before angiography in all patients and collected into citrate anti-coagulated tubes. Within 30 min, the blood was centrifuged at room temperature, and the plasma supernatant was immediately aliquoted and stored frozen at −80°C until analysis. The study was conducted according to the principles of the Declaration of Helsinki and approved by the institutional ethics committee. All patients gave informed consent for plasma collection and evaluation of the biomarkers.
Antibodies
Antibodies against RANTES (MAB278, AB278NA), NAP-2 (MAB393, BAF393), TSP-1(DY3074, BAF3074) and OPG (MAB8051, BAF805) were purchased from R&D systems, Abbington, United Kingdom. Antibodies against VWF (A0082, P0226) were purchased from DAKO, Denmark. VWF:pp levels were measured using in-house polyclonal rabbit antibodies raised as described earlier [20] . Bovine serum albumin (BSA) was purchased from Sigma (A7906; Zwijndrecht, the Netherlands). Supersignal ELISA pico chemiluminescent substrate was purchased from Thermo Scientific, USA.
ELISAs
Levels of RANTES, NAP-2, TSP-1, VWF, VWF:pp and OPG were measured using a semi-automated ELISA on a TECAN Freedom EVO robot (Tecan, Switzerland). All of the antigens were measured on separate 384 well Nunc maxisorp ELISA plates (Nunc, Denmark) in one measurement for each individual marker. Capture antibodies, MAB278 (0.5 μg/mL), MAB393 (1 μg/mL), DY3074 (0.5 μg/mL), MAB8051 (1 μg/mL), A0082 (0.0775 μg/mL) and the home made antibody against VWF:pp(5 μg/mL) were coated overnight at 4°C. Washing with five steps of phosphate-buffered saline (PBS)/0.5%Tween followed. Plasma samples were diluted 1/10 for RANTES, 1/80 for NAP-2 1/15 for TSP-1, 1/625 for VWF, 1/20 for VWF:pp and 1/8 for OPG. Every plate contained a 7 point calibration curve performed in quadruple. Incubations were made in PBS/1%BSA for 2 h and unbound fractions were washed again with (PBS)/0.5%Tween five times. Detection antibodies, AB-278-NA(1 μg/mL), BAF393(50 ng/mL), BAF3074-(100 ng/mL), P0226(275 ng/mL), home made antibody against VWF: pp(2.5 μg/mL) and BAF805(100 ng/mL) were added and washing as described earlier followed. Relative light units from HRP activity were measured with a chemiluminescent substrate (supersignal ELISA pico chemiluminescent substrate, Thermo Scientific, USA) by Spectramax reader (MDS Analytical Technologies). The lowest detection limit of the ELISA for OPG was 0.035 ng/mL. Therefore, high levels of OPG refer to values higher than 0.035 ng/mL.
End-points and follow-up
The primary end point was all-cause mortality followed over a period of 4 years. Information on deaths was obtained from hospital records, death certificates, or telephone contact with relatives of the patient or referring physician. Collection of baseline data and followup information was performed by personnel blinded to clinical diagnosis or endothelial or platelet marker levels.
Statistical analysis
The distribution of the data was analyzed with the KolmogorovSmirnov test. Categorical data were compared with the chi-square test. Continuous data with skewed distribution were compared with the Kruskal-Wallis rank-sum test. Survival analysis was performed by applying the Kaplan-Meier method and differences in survival were compared with the log-rank test. A multivariate Cox proportional hazards model was developed with variables in Table 1 that were regarded as potential confounders. Correlation between various markers was tested by calculating Spearman's correlation coefficient. All analyses were performed using S-plus statistical package (S-PLUS, Insightful Corp., Seattle, Washington). All tests were two-tailed and P values less than 0.05 were considered to indicate statistical significance.
Results
Patient characteristics
Forty-six patients died during the 4-years of follow-up. There were 34 cardiac deaths and 12 non-cardiac deaths of which the causes were the following: cancer (n= 4), infections (n= 4), stroke (n= 3) and chronic obstructive pulmonary disease (n= 1). Demographic and clinical characteristics of the survivors and non-survivors are shown in Table 1 . Angiographic characteristics are shown in Table 2 . There were significant differences between survivors and non-survivors with regard to age, diabetes, C-reactive protein (CRP) level, serum creatinine, diastolic blood pressure, chronic obstructive pulmonary disease, NYHA class and therapy at discharge with aspirin, beta-blockers or diuretics.
Platelet markers and clinical outcome
Levels of RANTES, NAP-2 and TSP-1 were comparable between the two groups and differences were not significant (Table 3) . There was no association between the levels of platelet markers and mortality (P=0.74 for association between RANTES level and mortality; P=0.91 for TSP-1; P=0.65 for NAP-2). As expected, platelet markers showed a strong correlation with each other (Fig. 1) .
Endothelial markers and clinical outcome
Distribution patterns of endothelial markers were evaluated with the Kolmogorov-Smirnov test and none of them showed a normal pattern. VWF correlated with CRP (Spearman R = 0.3; P b 0.001) and with VWF:pp (Spearman R = 0.72; P b 0.001; Fig. 2) .
Median values of VWF (12.2 μg/mL versus 7.86 μg/mL, P = 0.001) and VWF:pp (7.34 nM versus 6.17 nM, P =0.011) were higher in non-survivors compared to survivors. Kaplan-Meier estimates of mortality for VWF were 7.5% in the first quartile (n= 6 deaths), 12.2% in the second quartile (n= 10 deaths), 11.2% in the third quartile (n=9 deaths) and 25% in the fourth quartile (n= 21 deaths) of VWF, showing a significant increase in mortality risk for patients in the highest quartile of VWF versus the lower three quartiles (P = 0.004; Fig. 3 ). High levels of OPG were measured in 37 patients: 27 of them were survivors (9.2%) and 10 were non-survivors (21.7%, P = 0.011; Table 3 ). High OPG was also associated with a higher risk of mortality (P = 0.007; Fig. 4 ). Although a trend was observed, the association of VWF:pp in quartiles to mortality did not reach statistical significance (P = 0.12). A multivariate Cox proportional hazards model was used to assess whether VWF correlates with mortality independently of potential confounders. After adjusting for age, sex, diabetes and CRP, VWF correlated to mortality independently of other parameters (adjusted hazard ratio [HR]= 2.44, 95% CI 1.31-4.54), for 4th quartile versus the lower 3 quartiles, P = 0.005; Table 4 ). In the same model, VWF:pp was close to reaching statistical significance (adjusted HR= 1.21, 95% CI 0.99-1.48, P = 0.066) while OPG was not a significant correlate of mortality (HR = 1.56, 95% CI 0.75-3.24, P =0.229).
Discussion
The most important findings of the present study are: 1) Platelet activation markers are not associated with long-term mortality in patients with ACS undergoing PCI and 2) Elevated levels of endothelial markers at the time of the clinical presentation are associated with increased risk of long-term mortality in these patients.
Platelet activation in relation to abnormal thrombogenesis has been studied before in atrial fibrillation [21] but to our knowledge, the relationship of RANTES, NAP-2 and TSP-1 as platelet activation markers to secondary manifestations of ACS has been barely investigated [22] . Once released from activated platelets, RANTES binds the endothelium where it enables the migration and arrest of monocytes under flow conditions [23] . This is important in atherogenic processes such as neointima formation [24] . NAP-2 induces chemotaxis of monocytes, neutrophils and neutrophil degranulation and increased levels of this marker have been reported in patients with unstable coronary artery disease [25] . Increased levels of NAP-2 s precursor β-Thromboglobulin during acute myocardial infarction have been reported since the early 80s [26] [27] [28] , but its role in secondary manifestations of ACS has not been studied thoroughly. TSP-1 is a major constituent of platelet α-granules, plasma levels of which increase 100-fold when platelets are activated [29] but its role in coronary artery disease has not been convincingly demonstrated. While correlating strongly with each other, our study shows that RANTES, NAP-2 and TSP-1 are not associated with mortality in patients with ACS. A simple explanation might be that all patients with ACS are on anti-platelet therapy [30] [31] [32] . An increased risk of mortality due to hyper-reactive platelets could be efficiently neutralized by the use of aspirin or clopidogrel. In line with this suggestion, a recent study showed that clopidogrel treatment decreases RANTES secretion [33] .
In one of the earlier studies in this field, Montalescot et al. showed that raised plasma levels of VWF are an independent predictor of adverse clinical outcomes in unstable angina patients at 14 and 30 days of follow up [34] . Raised levels of VWF in patients with angina were shown to be prognostically valuable at an endpoint of 2 years also [6] . In both studies, higher VWF was thought to reflect endothelial perturbation. The propeptide of VWF plays an important role on the multimerization of VWF in endothelial cells but once in circulation, it circulates separately from VWF and it has a much shorter half-life. Due to the differences in half-life, the measurement of VWF and its propeptide can be used to distinguish between acute and chronic endothelial activation [35] . Accordingly, VWF:pp was reported to be increased in acute vascular disorders such as septicemia and thrombotic thrombocytopenic purpura, but only mildly elevated in chronic vascular disorders such as diabetes mellitus [36] . Although the predictive value of VWF levels has been studied in coronary syndromes [6, 7, 34, 37, 38] , to our knowledge, the relationship of VWF together with VWF:pp in relation to secondary manifestations of ACS has not been investigated before.
In this study, we found that raised VWF levels are associated with mortality in patients presenting with an ACS. Furthermore, we show for the first time, that in addition to increased VWF levels, high-risk ACS patients have mildly increased levels of its propeptide. This indicates that high-risk ACS patients are characterized by a chronic dysfunction of the endothelium.
The endothelium can be described as a dynamic endocrine organ which is involved in controlling the vasomotor tone, transport of nutrients and is metabolically very active. Its importance in thrombosis and disturbed blood flow is acknowledged for a long time. A recent study by Kanaji et al. [39] involving knockout models (VWF −/−) in mice expressing VWF only in endothelial cells or platelets, showed that VWF synthesized in endothelial cells is sufficient to support hemostasis (in VWF−/− mice) and that VWF produced in megakaryocytes/platelets can also contribute to hemostasis in the absence of endothelium-derived VWF. Clinically however, the importance of the endothelium in the prevention of secondary events has not been established yet unequivocally [15] . A relevant question in this context is whether the disruption of the endothelium is due to the infarct related coronary artery or is a more generalized phenomenon. VWF did not correlate with troponin I over the first 48 h of hospitalization in a study with unstable angina patients, indicating that the increase of VWF corresponds to a mechanism of disease other than myocardial cell damage [40] . The third protein localized in the endothelium that we have measured is OPG. OPG is a member of the tumor necrosis factor receptor family and a soluble decoy receptor for the osteoclast differentiation factor receptor-activator of nuclear factor κB ligand [41] . This pathway has been implicated in various inflammatory responses and atherogenesis. Furthermore, OPG serum levels were recently shown to predict the incidence of cardiovascular disease in the general population [42] and mortality in ACS patients [43] . Of importance in relation to our study, OPG is localized together with VWF and VWF:pp in the Weibel-Palade bodies of the endothelium [44] and might play a role in vascular injury [45] . We observed high levels of OPG in 37 of the patients included in this study. Interestingly, non-survivors were more likely to have higher OPG levels than survivors (Table 3) .
Our study has some limitations. We could not estimate absolute values of OPG on the majority of the samples of the study as they were below the detection limit. While the patient population of our study is larger than most of the earlier studies on the prognostic value of VWF [7, 34, 37, 38, 46] , it is still underpowered to reach a firm conclusion. Another limitation of our study which remains to be resolved in future studies is the role of active VWF in ACS patients undergoing PCI. Lastly, in this population, aggregation tests to measure the degree of the effectiveness of the anti-platelet therapy were not performed. However, strong points of our study include the use of a combination of markers to asses the role of platelets and the endothelium, a well-characterized sample of patients with ACS, a long follow up of 4 years and mortality as an endpoint.
In conclusion, our findings show that in ACS patients, chronic endothelial activation is associated with a poor prognosis. We did not find an association of platelet activation markers and mortality, which supports the notion that, markers of platelet activation are more valuable in guiding the treatment than to predict prognosis. Pharmacological targeting of the endothelium in ACS patients deserves further careful attention.
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